SOST and metabolic dysfunction-associated steatotic liver disease: Our study revealed a negative correlation between circulating sclerostin with FLI in NAFLD subjects (r=-0.243, p=0.002), while no correlation was found in normal control (r=0.178, p=0.111) (Figure 1).